BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock.

BioCardia Trading Down 2.4 %

BCDA stock opened at $2.04 on Wednesday. The firm has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.77. The stock has a market capitalization of $9.35 million, a P/E ratio of -0.49 and a beta of 1.25. BioCardia has a 12 month low of $1.84 and a 12 month high of $10.79.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.